Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €45.55 EUR
Change Today +1.19 / 2.69%
Volume 100.0
NK8 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:55 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NK8) Snapshot

Open
€44.86
Previous Close
€44.36
Day High
€46.51
Day Low
€44.63
52 Week High
05/29/15 - €46.51
52 Week Low
06/4/14 - €23.59
Market Cap
2.2B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
48.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVASIVE INC (NK8)

nuvasive inc (NK8) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NK8) Details

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product is Maximum Access Surgery (MAS), a minimally-disruptive surgical platform that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing process consist of Osteocel Plus and Osteocel Pro allograft (donated human tissue), which are cellular matrix products containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during non-spine. The company sells its products through independent sales agencies, directly-employed sales shareowners to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,500 Employees
Last Reported Date: 02/25/15
Founded in 1997

nuvasive inc (NK8) Top Compensated Officers

President and Chief Operating Officer
Total Annual Compensation: $545.7K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $380.5K
President of US Sales and Services
Total Annual Compensation: $375.0K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $454.1K
Consultant
Total Annual Compensation: $900.0K
Compensation as of Fiscal Year 2014.

nuvasive inc (NK8) Key Developments

NuVasive, Inc. Appoints Gregory T. Lucier as Chief Executive Officer

Effective on May 22, 2015, the Board of Directors of NuVasive, Inc. appointed Gregory T. Lucier as its Chief Executive Officer (in addition to his current role as Chairman of the Board). Mr. Lucier had served as Chairman of the Board and interim Chief Executive Officer since March 27, 2015 and as a member of the Company's Board since December 2013.

NuVasive, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 08:40 AM

NuVasive, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 08:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Quentin Blackford, Chief Financial Officer, Chief Accounting Officer and Executive Vice President.

NuVasive, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year 2015

NuVasive, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the period, revenue was $192,383,000 against $177,496,000 in the same period a year ago. Interest income was $419,000 against $217,000 in the same period a year ago. Income before income taxes was $49,282,000 against loss before income taxes was $33,628,000 in the same period a year ago. Net income was $31,397,000 against net loss of $18,533,000 in the same period a year ago. Net income attributable to the company was $31,560,000 or $0.61 per basic and diluted share against net loss attributable to the company $18,276,000 or $0.40 per basic and diluted share against in the same period a year ago. Net cash provided by operating activities was $26,023,000 against $23,300,000 in the same period a year ago. Purchases of property and equipment were $30,694,000 against $13,390,000 in the same period a year ago. Non-GAAP earnings were $14.3 million, or $0.29 per share. On a non-GAAP basis, the company reported net income of $14.3 million, or $0.29 per share, for the first quarter 2014. Purchase of intangible assets was $27,389,000. The company provides earnings guidance for the full year 2015. The company expects revenue of approximately $810.0 million, which includes an approximate $12.0 million of currency headwinds versus a prior expectation of an approximate $10.0 million currency impact for 2015, or approximately 6.0% growth compared to revenue of $762.4 million for 2014; on a constant currency basis revenue is expected to grow approximately 7.8%; GAAP earnings per share of approximately $1.12 compared to GAAP loss per share of ($0.36) for 2014; versus a prior expectation of $0.67 for 2015; Non-GAAP earnings per share of approximately $1.10, an increase of approximately 64.0% compared to non-GAAP earnings of $0.67 for 2014; unchanged from prior expectations for 2015; Non-GAAP operating margin of approximately 14.4%, an increase of approximately 300 basis points compared to 11.4% for 2014; unchanged from prior expectations for 2015; Adjusted EBITDA margin of approximately 24.6%, an increase of approximately 270 basis points compared to 21.9% for 2014; unchanged from prior expectations for 2015; GAAP effective tax expense rate of approximately 46.0%; versus a prior expectation of 49.0% for 2015; and Non-GAAP effective tax expense rate of approximately 46.0%; unchanged from prior expectations for 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NK8:GR €45.55 EUR +1.19

NK8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $55.54 USD -0.29
Globus Medical Inc $25.87 USD +0.12
Integra LifeSciences Holdings Corp $67.12 USD -1.02
Masimo Corp $35.10 USD -0.38
Thoratec Corp $45.48 USD -0.29
View Industry Companies
 

Industry Analysis

NK8

Industry Average

Valuation NK8 Industry Range
Price/Earnings 71.0x
Price/Sales 3.0x
Price/Book 3.6x
Price/Cash Flow 51.6x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit www.nuvasive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.